7th Annual General Meeting: Shareholders approve all proposals
Galenica AG / Key word(s): AGMEGM
7th Annual General Meeting: Shareholders approve all proposals
10.04.2024 / 17:29 CET/CEST
____________________________________________________________
Press release
The seventh Annual General Meeting of Galenica Ltd. was held on
10 April 2024 at the Kursaal in Bern. The shareholders approved
all the proposals put forward by the Board of Directors. They
also approved the proposed dividend of CHF 2.20 per share. All
members of the Board of Directors were re-elected for a term of
office of one year.
The seventh Annual General Meeting of Galenica Ltd. was attended
by 418 shareholders representing a total of 73.3% of the
registered voting shares of Galenica Ltd.
Re-elections to the Board of Directors and the Remuneration
Committee
Dr Markus R. Neuhaus, Pascale Bruderer, Bertrand Jungo, Judith
Meier, Prof. Dr med. Solange Peters, Dr Andreas Walde and Jörg
Zulauf were re-elected as members of the Board of Directors for a
term of office of one year. Dr Markus R. Neuhaus was re-elected
as Chairman of the Board of Directors for a term of office of one
year.
Bertrand Jungo, Pascale Bruderer, Prof. Dr med. Solange Peters
and Dr Andreas Walde were re-elected as members of the
Remuneration Committee for a term of office of one year, with the
Board of Directors re-appointing Bertrand Jungo as its chairman.
Approval of the 2023 financial statements and discharge of the
Board of Directors and Executive Committee
The shareholders also voted in favour of the proposals put
forward by the Board of Directors for the other agenda items: For
example, the 2023 Annual Financial Statements of Galenica Ltd.,
the Management Report and the 2023 consolidated Financial
Statements of the Galenica Group were approved and the actions of
the members of the Board of Directors and the Executive Committee
for the 2023 financial year were ratified. In a consultative
vote, the shareholders endorsed the Remuneration Report 2023,
with 94% voting in favour. For the first time, shareholders also
approved the report on non-financial matters pursuant to Article
964a of the Swiss Code of Obligations with 88.7% voting in
favour. The proposed binding maximum total remuneration for 2025
for the members of the Board of Directors and the Executive
Committee was also approved with 95.6% and 96.9% votes in favour,
respectively.
Sustainable and stable dividend
The Annual General Meeting also approved the dividend at the
prior-year level of CHF 2.20 per share proposed by the Board of
Directors. Half (CHF 1.10 per share) is paid out from the capital
contribution reserve and the other half from retained earnings.
This corresponds to a total expected distribution of CHF 109.6
million. Galenica strives to achieve strong and sustainable
dividend growth and plans to pay a dividend equal at least to the
previous year's level in 2024. The dividend for the 2023
financial year will be paid to shareholders from 16 April 2024.
Dates for the diary
23 May 2024: Galenica Group sales update
6 August 2024: Galenica Group half-year results 2024
24 October 2024: Galenica Group sales update
For further information, please contact:
Media Relations:
E-Mail: media@galenica.com
Tel. +41 58 852 85 17 Investor Relations:
E-Mail: investors@galenica.com
Tel. +41 58 852 85 31
Welcome to the Galenica network!
Our ambition is to meet the needs of patients and customers in
the Swiss healthcare market in a seamless, efficient and
personalised way. To achieve this, we operate the Galenica
network with over 20 Business Units, the strongest partners in
the Swiss healthcare market. We offer fully integrated solutions
both for customers and patients as well as for pharmacies,
drugstores, medical practices, hospitals, retirement and nursing
homes, home care providers, wholesalers, pharmaceutical
companies, health insurance funds and other partners.
Galenica is listed on the Swiss Stock Exchange (SIX Swiss
Exchange, GALE, security number 36,067,446). Additional
information concerning Galenica can be found at www.galenica.com.
____________________________________________________________
End of Media Release
____________________________________________________________
Language: English
Company: Galenica AG
Untermattweg 8
3027 Bern
Switzerland
Phone: +41 058 852 81 11
E-mail: info@galenica.com
Internet: https://www.galenica.com
ISIN: CH0360674466
Listed: SIX Swiss Exchange
EQS News ID: 1875561
End of News EQS News Service
____________________________________________________________
1875561 10.04.2024 CET/CEST